Business Description
Soleno Therapeutics Inc
NAICS : 541713
SIC : 2834
ISIN : US8342033094
Description
Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 431.2 | |||||
| Equity-to-Asset | 0.85 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 32.3 | |||||
| 3-Year EPS without NRI Growth Rate | 34 | |||||
| 3-Year FCF Growth Rate | 37 | |||||
| 3-Year Book Growth Rate | -16.6 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 45.38 | |||||
| 9-Day RSI | 43.52 | |||||
| 14-Day RSI | 42.3 | |||||
| 6-1 Month Momentum % | 64.62 | |||||
| 12-1 Month Momentum % | 666 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 11.23 | |||||
| Quick Ratio | 11.23 | |||||
| Cash Ratio | 11.11 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -81.4 | |||||
| Shareholder Yield % | -7.97 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -76.7 | |||||
| ROA % | -56.12 | |||||
| ROIC % | -292.49 | |||||
| ROC (Joel Greenblatt) % | -14039.31 | |||||
| ROCE % | -68.15 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 10.93 | |||||
| Price-to-Tangible-Book | 11.59 | |||||
| EV-to-EBIT | -27.71 | |||||
| EV-to-EBITDA | -28.76 | |||||
| EV-to-Forward-Revenue | 7.82 | |||||
| EV-to-FCF | -51.5 | |||||
| Price-to-Net-Current-Asset-Value | 12.47 | |||||
| Price-to-Net-Cash | 12.65 | |||||
| Earnings Yield (Greenblatt) % | -3.61 | |||||
| FCF Yield % | -1.88 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Soleno Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -2.508 | ||
| Beta | -3.18 | ||
| Volatility % | 347.28 | ||
| 14-Day RSI | 42.3 | ||
| 14-Day ATR (€) | 0.299177 | ||
| 20-Day SMA (€) | 34.893 | ||
| 12-1 Month Momentum % | 666 | ||
| 52-Week Range (€) | 3.43 - 48.4 | ||
| Shares Outstanding (Mil) | 36.86 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Soleno Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Soleno Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Soleno Therapeutics Inc Frequently Asked Questions
What is Soleno Therapeutics Inc(FRA:6XC)'s stock price today?
The current price of FRA:6XC is €34.78. The 52 week high of FRA:6XC is €48.40 and 52 week low is €3.43.
When is next earnings date of Soleno Therapeutics Inc(FRA:6XC)?
The next earnings date of Soleno Therapeutics Inc(FRA:6XC) is 2024-08-08 Est..
Does Soleno Therapeutics Inc(FRA:6XC) pay dividends? If so, how much?
Soleno Therapeutics Inc(FRA:6XC) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers